Targeting the underlying pathobiology of ESCC

December 6, 2021

Listen to leading experts provide an update on the underlying pathobiology of esophageal squamous cell carcinoma, and review current and emerging therapies.

The expert

  • Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan

This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an independent medical education grant from Novartis. This activity is provided by touchIME.

For further information visit our website:

Podbean App

Play this podcast on Podbean App